Biotech Blog
Article
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
5/25/12 5:30AM
Video
Senior columnist Adam Feuerstein says the ASCO Cancer Conference is the next big thing in biotech.
5/25/12 5:30AM
Article
CDX-011 works best in breast cancers with high levels of a protein linked to more aggressive disease.
5/23/12 4:01PM
Article
Galena has questions that need answering about its breast cancer vaccine NeuVax at the upcoming ASCO confab.
5/22/12 2:23PM
Article
TheStreet's Adam Feuerstein has compiled a list of drugs with crucial, stock-moving clinical trial catalysts for the remainder of 2012.
5/22/12 8:56AM
Article
TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.
5/17/12 11:55AM
Article
Array Biopharma, Exelixis,Onyx Pharma and Pharmacyclics among cancer drug developers releasing new data ahead of the big ASCO meeting.
5/17/12 6:19AM
Article
New drugs that target genetic weakness in cancer in the spotlight as ASCO previews its closely followed conference.
5/16/12 6:01PM
Article
Array Biopharma, Exelixis, Aveo and Pharmacyclics among cancer drug developers releasing new data ahead of the big ASCO meeting.
5/16/12 6:00PM
Article
A closer look at 13F regulatory filings in the biotech sector for the first quarter.
5/16/12 7:10AM
Article
Thoughts and questions following last week's positive FDA panel for Arena's weight-loss drug lorcaserin.
5/14/12 3:09PM
Article
Join TheStreet biotech columnist Adam Feuerstein as he provides live coverage of the FDA advisory panel reviewing Arena Pharma's obesity drug lorcaserin.
5/10/12 7:43AM
Article
FDA experts will vote Thursday on whether to recommend approval of Arena's lorcaserin for weight loss.
5/8/12 12:10PM
Article
With its cystic fibrosis drug business flourishing, making the case for Vertex to be worth even more is easy.
5/7/12 4:06PM
Article
Vertex plans to start a phase III study soon; if approved, the two-drug therapy could treat half of cystic fibrosis patients worldwide.
5/7/12 9:57AM
Article
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
5/4/12 7:34AM
Video
Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.
5/4/12 6:00AM
Article
An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012.
5/2/12 1:45PM
Article
Hedge fund rips into Savient management and demands company liquidate remaining assets.
5/1/12 3:06PM
Article
Getting ready for the May 10 FDA advisory panel reviewing Arena's obesity drug lorcaserin.
5/1/12 8:25AM
Article
Celldex can't present key breast cancer data at ASCO annual meeting, will hold webcast on May 23.
5/1/12 7:00AM
Article
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
4/27/12 6:00AM
Video
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
4/27/12 5:00AM
Article
Amarin's prescription fish oil brushes away a challenge from competitor Omthera Pharmaceuticals.
4/26/12 10:41AM
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Connect with TheStreet